AUTHORS
Joselle M Cook, M.D., Nadine Abdallah I, MD2, Wilson Gonsalves, MD3, S. Vincent Rajkumar, MD4, Shaji Kumar, MD5, Mohammad Mustafa6, Rahma Warsame, MD7, Megan Weivoda, PhD8, Alex Weston, PhD9, Brandon Grossardt, MS10, Andrea Ferrero, PhD11, Stephen Broski, MD12, Sharmila Giri, MS13, Fang-Shu Ou, PhD14, Celine Vachon, PhD15, Francis Baffour, MD16
AFFILIATIONS
1 Mayo Clinic, Rochester, Minnesota, United States
2 Mayo Clinic, Rochester, Minnesota, United States
3 Mayo Clinic, Rochester, Minnesota, United States
4 Mayo Clinic, Rochester, Minnesota, United States
5 Mayo Clinic, Rochester, Minnesota, United States
6 Mayo Clinic, Rochester, Minnesota, United States
7 Mayo Clinic, Rochester, Minnesota, United States
8 Mayo Clinic, Rochester, Minnesota, United States
9 Mayo Clinic, Rochester, Minnesota, United States
10 Mayo Clinic, Rochester, Minnesota, United States
11 Mayo Clinic, Rochester, Minnesota, United States
12 Mayo Clinic, Rochester, Minnesota, United States
13 Mayo Clinic, Rochester, Minnesota, United States
14 Mayo Clinic, Rochester, Minnesota, United States
15 Mayo Clinic, Rochester, Minnesota, United States
16 Mayo Clinic, Rochester, Minnesota, United States
ABSTRACT
Background: Patients with monoclonal gammopathy of undetermined significance (MGUS) have an increased risk of skeletal complications, but whether CT-derived estimates of vertebral bone quality progressively deteriorates during the MGUS disease course before progression to multiple myeloma (MM) remains unknown. CT imaging also permits simultaneous assessment of skeletal muscle composition, another important determinant of musculoskeletal health. We evaluated longitudinal changes in CT-derived vertebral bone attenuation and body composition among patients with MGUS.
Methods: We performed a retrospective longitudinal study of patients with MGUS who underwent clinically acquired CT scans. Longitudinal trajectories of vertebral bone attenuation in Hounsfield’s units (HU) and CT-derived body composition measures at the L3 vertebral level were evaluated using multivariable linear mixed-effects models with patient-specific random intercepts and slopes, adjusted for age at MGUS diagnosis, sex, and timing of each scan relative to diagnosis. For patients who progressed to MM, imaging follow-up was censored at the time of MM diagnosis so that only pre-progression scans were analyzed.
Results: The cohort included 1,528 patients (mean age 67.8 years; 61.5% male) contributing 5,223 CT scans over median (IQR) follow up time of 4.26 (1.1, 7.17) years. Twenty-nine patients (1.9%) progressed to MM during follow-up. Mean bone attenuation was 310.86 (SD 121.66). The longitudinal trajectories differed between bone and skeletal muscle. Vertebral bone attenuation demonstrated a +3.3 HU/year increase over time (95% CI 1.7-4.9; P=0.0001), consistent with no clinically meaningful deterioration in vertebral bone quality during the MGUS disease course. In contrast, skeletal muscle composition showed declines in skeletal muscle area (-1.35 cm²/year, 95% CI -1.90 to -0.79; P<0.0001) and muscle attenuation (-0.47 HU/year, 95% CI -0.70 to -0.24; P=0.0001), accompanied by increasing intermuscular adipose tissue (+0.38 cm²/year, 95% CI 0.23-0.52; P<0.0001). Visceral adipose tissue remained stable (P=0.843), whereas subcutaneous adipose tissue declined over time (-2.24 cm²/year, P=0.006). Older age at MGUS diagnosis was independently associated with lower vertebral bone attenuation. The limited number of MM progression events precluded meaningful comparisons of imaging trajectories between progressors and non-progressors.
Conclusions: Despite the known skeletal fragility associated with MGUS, these CT-derived vertebral bone attenuation measures remained stable over time in this large longitudinal cohort, providing no evidence of progressive vertebral bone deterioration. This study provides one of the first comprehensive longitudinal characterizations of CT-derived musculoskeletal measures during the MGUS disease course.
DISCLOSURES
Joselle M Cook, M.D.: Kite Pharmaceuticals - Honoraria; Janssen Pharmaceuticals - Research Funding; Regeneron - Consultancy (Includes expert testimony); Sanofi - Consultancy (Includes expert testimony)